- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Bortezomib ; volume:31 ; number:04 ; year:2010 ; pages:143-144
Indian journal of medical & paediatric oncology ; 31, Heft 04 (2010), 143-144
- Contributor
-
Rajappa, Senthil
- DOI
-
10.4103/0971-5851.76199
- URN
-
urn:nbn:de:101:1-2021090215374292320299
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Rajappa, Senthil
Other Objects (12)
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
Bortezomib in der Therapie des Pankreaskarzinoms
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Die Kombination von Hyperthermie und Bortezomib im Mantelzelllymphom
Physicochemical stability of bortezomib solutions for subcutaneous administration
Development and characterization of liposomal formulation of bortezomib
Bortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy
Apoptoseinduktion durch BH3-Mimetika und Bortezomib in Sarkomzelllinien
Die Kombination von Hyperthermie und Bortezomib im Mantelzelllymphom
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Bortezomib : von der Innovation zum Therapiestand beim multiplen Myelom
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
Bortezomib in der Therapie des Pankreaskarzinoms
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Die Kombination von Hyperthermie und Bortezomib im Mantelzelllymphom
Physicochemical stability of bortezomib solutions for subcutaneous administration
Development and characterization of liposomal formulation of bortezomib
Bortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy
Apoptoseinduktion durch BH3-Mimetika und Bortezomib in Sarkomzelllinien
Die Kombination von Hyperthermie und Bortezomib im Mantelzelllymphom
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
Bortezomib : von der Innovation zum Therapiestand beim multiplen Myelom
Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma
Bortezomib in der Therapie des Pankreaskarzinoms
Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
Bortezomib sensitizes neuroblastoma for TRAIL-induced apoptosis
Die Kombination von Hyperthermie und Bortezomib im Mantelzelllymphom
Physicochemical stability of bortezomib solutions for subcutaneous administration
Development and characterization of liposomal formulation of bortezomib
Bortezomib Treatment for Refractory PLA2R-Positive Membranous Nephropathy
Apoptoseinduktion durch BH3-Mimetika und Bortezomib in Sarkomzelllinien
Die Kombination von Hyperthermie und Bortezomib im Mantelzelllymphom
Autologous Stem Cell Collection after Daratumumab, Bortezomib, Thalidomide, and Dexamethasone versus Bortezomib, Cyclophosphamide, and Dexamethasone in Newly Diagnosed Multiple Myeloma